Ex-FDA neuro chief Billy Dunn is taking a spin through the revolving door with biopharma — and that's a problem
It’s been less than three months since the FDA put out word that Billy Dunn had left the agency following a controversial run highlighted by a calamitous decision to approve Biogen’s Alzheimer’s drug, Aduhelm. And he didn’t leave much room for a break.
On Tuesday night we learned, via press release, that Prothena CEO Gene Kinney had signed him up for a lucrative board post, where no doubt Dunn can play a helpful role in guiding them through the FDA process as they advance their own neuro drugs through the clinic.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.